Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

18 May 2012

Abstract excerpt

PURPOSE: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to probability of recurrence. EXPERIMENTAL DESIGN: Global miRNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Estrogen and related hormone effects
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22623953
DOI: 10.1371/journal.pone.0036170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG StudyPMID 22623953Read ↗

A microRNA Signature Associated with Early Recurrence in Breast CancerSemantic proximity Read ↗

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast CancerSemantic proximity Read ↗

Breast cancer lncRNA-microRNA categories: new targets for therapeutic interventionSemantic proximity Read ↗

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.Semantic proximity Read ↗

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentSemantic proximity Read ↗

Refinement of breast cancer molecular classification by miRNA expression profilesSemantic proximity Read ↗

MicroRNAs, a Promising Target for Breast Cancer Stem Cells.Semantic proximity Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER statusSemantic proximity Read ↗

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer - data from the randomized SBII:2 trialSemantic proximity Read ↗

Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast CancerSemantic proximity Read ↗

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.